Sionna Therapeutics, Inc.
SIONNASDAQHealthcareBiotechnology
Regular session
$5.33
+$0.04 · +0.76%
Aug 24, 1:41 PM ET
SION company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
43/100
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
37
Expensive
Momentum
61
Gaining
Sentiment
51
Mixed
Risk resilience
53
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteOperating as a biopharmaceutical company, Sionna Therapeutics, Inc. is dedicated to transforming the treatment landscape for individuals with cystic fibrosis. This is achieved by developing innovative medicines designed to restore the normal function of the cystic fibrosis transmembrane conductance regulator.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Michael Cloonan
- Listed since
- Feb 7, 2025
- Employees
- 59
Market position
Day range
Current $5.33
$5.21$5.50
52-week range
Current $5.33
$4.01$54.97
- Open
- $5.28
- Previous close
- $5.29
- Volume
- 916.07K
- 0.68× average
- Average volume
- 1.34M
- Average daily volume
- Market cap
- 240.65M USD
- Beta
- 1.32
- Market reference 1
- 50-day average
- $36.1054
- -85.24% below average
- 200-day average
- $38.6247
- -86.20% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 1.59B USD
- P/E (TTM)
- -2.44×
- P/B (TTM)
- 0.91×
- P/S (TTM)
- 0×
- EV / EBITDA
- -21.36×
- Earnings yield
- -4.58%
- Free cash flow yield
- -4.06%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -24.53%
- Return on assets
- -23.09%
- Return on invested capital
- -28.20%
Financial health
- Debt / equity
- 0.03×
- Current ratio
- 20.61×
- Altman Z-score
- 6.57
- Piotroski F-score
- 0 of 9
Financial statements
Income trends
Operating income
−88.98M USD-26.12%
Net income
−75.27M USD-22.01%
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cost of goods sold | 647K USD | 668K USD | — | — |
| Gross profit | −647K USD | −668K USD | — | — |
| Research and development | 60.26M USD | 57.29M USD | 40.63M USD | 34.61M USD |
| Selling, general, and administrative | 28.72M USD | 13.27M USD | 9.71M USD | 6.77M USD |
| Operating expenses | 88.34M USD | 69.89M USD | 50.33M USD | 41.37M USD |
| Interest income | 13.3M USD | 8.17M USD | 2.77M USD | 1.13M USD |
| Depreciation and amortization | 647K USD | 668K USD | 583K USD | 122K USD |
| Operating income | −88.98M USD | −70.56M USD | −50.33M USD | −41.37M USD |
| Net income | −75.27M USD | −61.69M USD | −47.26M USD | −40.24M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 43%
- 3 beats, 4 misses, 0 met estimates
- Average EPS surprise
- -21.94%
- 7 comparable reports
- Latest EPS result
- -0.66
- Estimate -0.65 · Miss by 1.54%
EPS: actual versus estimate
Recent quarterly results
ActualEstimate
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$27.20
410.32% upsidePast 12 months12-month forecastHigh $60.00Average $27.20Low $5.00
Recent analyst actions
WedbushdowngradeOutperformNeutral
CitizensmaintainMarket Outperform
Freedom BrokerdowngradeBuyHold
StifelmaintainBuy
Jones TradingmaintainBuy
RBC CapitaldowngradeSector PerformUnderperform
SION news
SION peers
ETFs holding SION
Funds reporting this stock among their holdings, ordered by reported position size.
ETFMarket valueWeightAUMExpense ratioPrice / 1D
Vanguard Morningstar Total Stock Market ETFVTI44.05M0.00%2.3T USD0.03%$376.93-0.35%
Vanguard Extended Market ETFVXF7.84M0.01%93.7B USD0.05%$243.1-0.99%
Vanguard Russell 2000 ETFVTWO4.88M0.03%17.4B USD0.06%$120.32-0.77%
State Street SPDR S&P Biotech ETFXBI3.54M0.03%11.39B USD0.35%$164.07-1.00%
iShares Russell 2000 ETFIWM2.51M0.00%81.62B USD0.19%$297.6-0.79%
Vanguard U.S. Momentum Factor ETFVFMO2.42M0.12%1.8B USD0.13%$228.53-1.72%
Vanguard Health Care ETFVHT1.93M0.01%20.9B USD0.09%$326.83-0.27%
iShares Biotechnology ETFIBB1.04M0.01%10.75B USD0.44%$212.08-0.70%Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 44.05M
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $376.93-0.35%
Vanguard Extended Market ETFVXF- Market value
- 7.84M
- Weight
- 0.01%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $243.1-0.99%
Vanguard Russell 2000 ETFVTWO- Market value
- 4.88M
- Weight
- 0.03%
- AUM
- 17.4B USD
- Expense ratio
- 0.06%
- Price / 1D
- $120.32-0.77%
State Street SPDR S&P Biotech ETFXBI- Market value
- 3.54M
- Weight
- 0.03%
- AUM
- 11.39B USD
- Expense ratio
- 0.35%
- Price / 1D
- $164.07-1.00%
iShares Russell 2000 ETFIWM- Market value
- 2.51M
- Weight
- 0.00%
- AUM
- 81.62B USD
- Expense ratio
- 0.19%
- Price / 1D
- $297.6-0.79%
Vanguard U.S. Momentum Factor ETFVFMO- Market value
- 2.42M
- Weight
- 0.12%
- AUM
- 1.8B USD
- Expense ratio
- 0.13%
- Price / 1D
- $228.53-1.72%
Vanguard Health Care ETFVHT- Market value
- 1.93M
- Weight
- 0.01%
- AUM
- 20.9B USD
- Expense ratio
- 0.09%
- Price / 1D
- $326.83-0.27%
iShares Biotechnology ETFIBB- Market value
- 1.04M
- Weight
- 0.01%
- AUM
- 10.75B USD
- Expense ratio
- 0.44%
- Price / 1D
- $212.08-0.70%
Continue in GoAI
Research SIONresearch.disclaimer